Sotalol

證據等級: L5

預測適應症: 7 個

One-Sentence Summary

Sotalol is a non-selective beta-blocker with Class III antiarrhythmic activity; no approved-indication text or MOA record is available in this evidence pack (registry/label data gap). Among the seven TxGNN-predicted indications reviewed, the model’s single highest-ranked candidate (sick sinus syndrome) is mechanistically implausible and possibly contraindicated, while the strongest-evidenced candidate is rhythm control of atrial fibrillation/flutter for stroke risk reduction, supported by 20 clinical trials (including a completed Phase 3 RCT with 706 patients) and 20 publications. This represents confirmation of an already-established antiarrhythmic use rather than a novel repurposing discovery.

Quick Overview

Item	Content
Original Indication	Not available — no license records in this evidence pack (drug not marketed in this jurisdiction)
Predicted New Indication	Atrial fibrillation/flutter rhythm control for stroke risk reduction (mapped from TxGNN term “stroke disorder”)
TxGNN Prediction Score	99.44% (rank 4 of 7 candidates reviewed)
Evidence Level	L1
Market Status	Not marketed (未上市)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available for sotalol in this evidence pack (data gap DG002). Based on the pharmacology reflected in the literature and trial evidence, sotalol combines non-selective beta-adrenergic blockade with Class III antiarrhythmic activity (IKr/repolarization prolongation), which underlies its established role in maintaining sinus rhythm in atrial fibrillation (AF) and treating ventricular arrhythmias.

TxGNN’s top-ranked prediction by raw score was sick sinus syndrome (99.76%), but the drug’s own repurposing rationale flags this as mechanistically backwards: sick sinus syndrome typically requires increasing heart rate (often with pacemaker support), whereas sotalol suppresses sinus node automaticity and conduction — a likely relative contraindication rather than a treatment opportunity. Similarly, Wildervanck syndrome, sarcoglycanopathy, macrocephaly/dysmorphic facies/psychomotor retardation syndrome, and “obsolete susceptibility to ischemic stroke” (a deprecated ontology term) have no supporting trials or literature and are best explained as knowledge-graph noise. Manic bipolar affective disorder is supported only by drug-interaction/safety literature warning that beta-blockade can worsen antipsychotic-associated QT prolongation risk — again a safety signal, not efficacy evidence.

By contrast, the “stroke disorder” prediction maps to a well-documented, evidence-backed application: AF is a major driver of ischemic stroke, and sotalol is used clinically to maintain sinus rhythm in AF/flutter, thereby indirectly reducing stroke risk. This is corroborated by a completed VA cooperative Phase 3 RCT (CSP #399, n=706) directly testing sotalol for AF rhythm control, plus a large systematic review/network meta-analysis (n=87,810) comparing sotalol against dronedarone in AF safety outcomes. This report therefore focuses on this best-evidenced candidate rather than the raw top-scored TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00007605	Phase 3	Completed	706	VA Cooperative Study (CSP #399): amiodarone vs. sotalol vs. class I agents for maintaining sinus rhythm in AF — direct RCT evidence for sotalol.
NCT05279833	N/A (SLR/NMA)	Completed	87,810	Systematic literature review/network meta-analysis comparing dronedarone (Multaq) vs. sotalol safety/effectiveness in AF patients.
NCT00523978	Phase 3	Completed	245	STOP AF trial: cryoablation vs. antiarrhythmic drugs (flecainide, propafenone, or sotalol) in paroxysmal AF refractory patients.
NCT02145546	Phase 4	Unknown	600	Compares amiodarone, sotalol, and propafenone for AF burden reduction in sick sinus syndrome patients post-pacing.
NCT07405671	Phase 4	Not yet recruiting	988	Flecainide vs. standard rhythm-control drugs (sotalol/amiodarone) in AF with stable coronary artery disease.
NCT02389218	Phase 4	Completed	13	Medical therapy vs. cryoballoon ablation in early persistent AF; small sample, drug regimen not sotalol-specific.
NCT00911508	N/A	Completed	2,204	CABANA trial: catheter ablation vs. antiarrhythmic drug therapy (rate/rhythm control) for AF.
NCT01856075	N/A	Completed	1,015	Real-world observational study of dronedarone vs. other antiarrhythmic agents (including sotalol) for AF.
NCT06322017	N/A	Recruiting	294	Early pulmonary vein isolation vs. usual (drug) treatment in AF patients over age 75.
NCT02459574	N/A	Completed	321	AF ablation vs. antiarrhythmic drug therapy for reducing hospitalization from recurrent AF.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9576159	1998	Randomized, double-blind	Am J Cardiol	Low-dose amiodarone vs. sotalol for suppression of recurrent symptomatic AF (n=70).
29954667	2019	Cohort	Int J Cardiol	Efficacy and adverse effects of sotalol in adults with congenital heart disease.
37485722	2023	Cohort/Comparative	Circ Arrhythm Electrophysiol	Dronedarone vs. sotalol head-to-head effectiveness/safety in antiarrhythmic-naïve veterans with AF.
1281807	1992	Clinical Study	Int J Cardiol	Efficacy and safety of sotalol in patients with complex ventricular arrhythmias (n=626 pooled).
8346725	1993	Clinical Study	Am J Cardiol	Hemodynamic effects of oral sotalol during dose titration in patients with ventricular arrhythmias.
7509121	1994	Clinical Study	Am J Cardiol	Response to sotalol predicts response to amiodarone in sustained ventricular tachycardia with CAD.
25428811	2015	Cost-effectiveness analysis	Kardiol Pol	Cost-effectiveness of dronedarone vs. amiodarone, propafenone, and sotalol in AF.
28496906	2013	Cohort	J Atr Fibrillation	Cardiovascular/stroke/CHF/liver injury risk: dronedarone vs. amiodarone and other antiarrhythmics.
38011245	2023	Review	Circulation	Contemporary AF management in hypertrophic cardiomyopathy, including antiarrhythmic drug options.
39077579	2023	Review	Rev Cardiovasc Med	Management of AF during pregnancy, including antiarrhythmic drug risk-benefit considerations.

US Market Information

No marketing authorization records are present in this evidence pack (total_licenses: 0, market status: 未上市 / not marketed). Registry/label data will need to be sourced separately before this candidate can advance.

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data are available in this evidence pack (TFDA label data collection is flagged as a Blocking gap — DG001).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The AF/stroke-risk-reduction indication is backed by L1-level evidence (≥2 completed Phase 3 trials plus a large comparative safety review), consistent with sotalol’s known, already-established antiarrhythmic use rather than a speculative repurposing target. However, this is a confirmation of existing pharmacology, not a novel discovery, and a critical safety data gap remains unresolved.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/label warnings, contraindications, and QT-prolongation/proarrhythmia precautions before any S1 safety review
Obtain original approved-indication text and MOA documentation (DG002) to complete mechanistic comparison
Confirm route/dosage-form availability for the target population
Disregard TxGNN’s raw top-ranked candidates (sick sinus syndrome, Wildervanck syndrome, sarcoglycanopathy, macrocephaly/dysmorphic-facies syndrome, obsolete stroke-susceptibility term) — none have supporting evidence, and sick sinus syndrome specifically carries a plausible contraindication risk
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.